233 related articles for article (PubMed ID: 31424408)
1. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer's Disease Clinical Cohort.
Pavlik VN; Chan W; Darby E
J Alzheimers Dis; 2019; 71(2):659-669. PubMed ID: 31424408
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
3. Progression of Alzheimer's Disease: A Longitudinal Study in Norwegian Memory Clinics.
Eldholm RS; Barca ML; Persson K; Knapskog AB; Kersten H; Engedal K; Selbæk G; Brækhus A; Skovlund E; Saltvedt I
J Alzheimers Dis; 2018; 61(3):1221-1232. PubMed ID: 29254085
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
5. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
7. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
8. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
10. Is functional decline necessary for a diagnosis of Alzheimer's disease?
Park KW; Pavlik VN; Rountree SD; Darby EJ; Doody RS
Dement Geriatr Cogn Disord; 2007; 24(5):375-9. PubMed ID: 17914262
[TBL] [Abstract][Full Text] [Related]
11. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
[TBL] [Abstract][Full Text] [Related]
12. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS
Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181
[TBL] [Abstract][Full Text] [Related]
13. Differences in Alzheimer disease clinical trial outcomes based on age of the participants.
Schneider LS; Kennedy RE; Wang G; Cutter GR
Neurology; 2015 Mar; 84(11):1121-7. PubMed ID: 25681452
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
15. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.
Rountree SD; Chan W; Pavlik VN; Darby EJ; Siddiqui S; Doody RS
Alzheimers Res Ther; 2009 Oct; 1(2):7. PubMed ID: 19845950
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
Suh GH; Ju YS; Yeon BK; Shah A
Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
[TBL] [Abstract][Full Text] [Related]
17. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial.
Sevigny JJ; Peng Y; Liu L; Lines CR
Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):119-24. PubMed ID: 19949163
[TBL] [Abstract][Full Text] [Related]
18. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
19. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging.
Benoit JS; Chan W; Piller L; Doody R
Am J Alzheimers Dis Other Demen; 2020; 35():1533317520918719. PubMed ID: 32573256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
